Cartalax
Chondroprotective tripeptide bioregulator (Ala-Glu-Asp) that activates chondrogenic differentiation through SOX9/COL2A1/aggrecan upregulation, reverses senescence-associated secretory phenotype in aging chondrocytes, and provides geroprotective effects through SIRT-6 upregulation and p16/p21/p53 suppression
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
200 mcg
Compound profile
Scientific & efficacy data
Anti-Aging
Peptide profile
Moderate human trials
Cartalax
200 mcg · Once daily
Molecular formula
C12H19N3O8
- Mol. weight
- 333.3 g/mol
- CAS number
- Not yet registered (research compound)
- PubChem
- 87815447
- Developed · 1990s-2000s (part of the Khavinson cartilage/connective tissue bioregulator research program)
- Cartilage Therapeutics
Cartilage Therapeutics Inc.
Amino acid sequence
KGDG-X-KGDGAnti-Aging
Cartalax directly addresses the molecular hallmarks of connective tissue aging through SASP reversal (p16, p21, p53 normalization), SIRT-6 upregulation, MMP-9 inhibition, and IGF1 stimulation (3.5-5.6 fold) — providing comprehensive geroprotective activity in the musculoskeletal system at the gene expression level via DNA minor groove interaction
Healing & Recovery
Activates chondrogenic differentiation from stem cells by upregulating SOX9 (master regulator), type II collagen, aggrecan, and COMP at 10-fold greater potency than crude cartilage extracts — while simultaneously reducing cartilage-degrading MMP-9 and inflammatory cytokines TNF-α and IL-1α to shift the metabolic balance from destruction to regeneration
Hormone Support
Stimulates IGF1 gene expression by 3.5-5.6 fold and modulates irisin (a telomere-elongating myokine), providing hormonal support for tissue growth and cellular rejuvenation pathways that complement the direct cartilage repair mechanisms
Dosing
How much do I take?
200 mcg · once daily
200 mcg
Once daily
Covers timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for cartilage regeneration and protection in age-related osteoarthritis & connective tissue repair and maintenance in aging individuals
Best for
Cartilage regeneration and protection in age-related osteoarthritis
Cartalax is particularly well-suited for individuals focused on cartilage regeneration and protection in age-related osteoarthritis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Connective tissue repair and maintenance in aging individuals
Cartalax is particularly well-suited for individuals focused on connective tissue repair and maintenance in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
Cartalax is particularly well-suited for individuals focused on geroprotective therapy targeting the sirt-6/senescence axis in musculoskeletal tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy
Cartalax is particularly well-suited for individuals focused on complementing conventional osteoarthritis treatments with bioregulatory peptide therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Cartalax with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Oral (capsule) · Sublingual (liquid drops)
Route
Cartalax is administered Oral (capsule)—no injection required
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
Cartalax (polypeptide complex from bovine cartilage) has not undergone formal FDA approval or rigorous clinical safety trials.
The safety profile is based on traditional use in Russia and Eastern Europe as a cartilage extract supplement, with limited published safety data.
As a complex mixture of polypeptides, collagens, and proteoglycans, the actual active components and their pharmacology are undefined, making toxicity prediction impossible.
Potential allergic reactions to bovine proteins exist, and contamination risks from source animal tissues cannot be ruled out without pharmaceutical manufacturing standards.
Evidence consists of observational clinical use in Russian medical practice spanning several decades and a small number of open-label clinical studies without proper controls.
No preclinical toxicology studies, Phase 1 dose-escalation data, Phase 2 efficacy trials, or Phase 3 confirmatory studies exist. Published research is primarily in Russian-language journals and lacks rigorous methodology by modern standards.
Common side effects · experienced by some users
Mild injection site reaction
Pain, redness, or slight swelling at the subcutaneous injection site when injectable form is used. Common with peptide injections.
Management: Rotate injection sites. Apply cold compress if needed. Resolves spontaneously within 24-48 hours.
Mild GI discomfort
Slight nausea or stomach discomfort with oral capsule administration, particularly on an empty stomach.
Management: Take with a small amount of food. Consider sublingual form to bypass the GI tract.
Mild fatigue
Slight fatigue during the initial days as the body adjusts to epigenetic gene expression changes in connective tissues.
Management: Usually resolves within 3-5 days. Rest as needed.
Transient joint stiffness
Temporary increase in joint stiffness as cartilage repair processes initiate and the tissue remodeling balance shifts from catabolism to anabolism.
Management: Gentle movement and stretching. This may indicate active tissue repair. Should improve as the treatment course progresses.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Cartalax
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Cartalax should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Sigumir (joint and bone peptide bioregulator — provides complementary multi-peptide complex support for musculoskeletal tissue alongside Cartalax's targeted AED mechanism) — May be used together under medical guidance.
- Safe:Glucosamine/Chondroitin (traditional joint support supplements — provides structural building blocks while Cartalax activates the gene expression for cartilage matrix production) — May be used together under medical guidance.
- Safe:Ventfort (vascular peptide bioregulator — supports blood supply to cartilage and joint tissues, complementing Cartalax's tissue-level effects) — May be used together under medical guidance.
With medications
- Caution:High-dose NSAIDs chronically — may mask the gradual improvements from Cartalax and some evidence suggests chronic NSAID use can impair cartilage repair — Use with caution—discuss with your healthcare provider.
- Caution:Immunosuppressive medications without medical guidance — Cartalax has immunomodulatory effects through cytokine regulation — Use with caution—discuss with your healthcare provider.
- Caution:Corticosteroid joint injections immediately preceding Cartalax treatment — local immunosuppression may impair the peptide's bioregulatory effects — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Cartalax. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Moderate human trials · first signs days 1-10
Evidence level
Moderate human trials
(Phase 1-2)
Regulatory status
Research compound
Onset of effects
Gradual
(3-4 weeks)
How it works
Cartalax is a synthetic peptide designed to mimic cartilage-building signals in the body, helping regenerate damaged joint cartilage through anti-inflammatory mechanisms and promotion of chondrocyte activity.
The deeper mechanism
Cartalax functions as a bioactive peptide that activates cartilage-specific signaling pathways, promoting chondrocyte differentiation and extracellular matrix synthesis.
It modulates inflammatory mediators through toll-like receptor modulation and NF-κB pathway suppression, reducing joint inflammation and promoting matrix deposition of type II collagen and proteoglycans.
What to expect
Days 1-10
What you might notice
- No significant joint changes initially — epigenetic cartilage repair takes weeks to manifest
- Possible mild initial side effects (GI discomfort, fatigue, transient stiffness) that resolve
- The AED tripeptide is binding DNA minor groove sequences and beginning to shift gene expression
- SASP reversal is starting: p16/p21/p53 suppression and SIRT-6 upregulation are underway
What's normal
- Cartalax works at the gene expression level — functional improvements require time for protein synthesis and tissue remodeling
- SOX9 and cartilage matrix gene activation are beginning during this period
- MMP-9 inhibition is starting to slow cartilage degradation
- No pain relief expected yet — Cartalax is not an analgesic
What's next
- Continue the full treatment course (10-20 days)
- Track joint function, stiffness, and mobility for comparison over coming weeks
- Anti-inflammatory cytokine effects (TNF-α, IL-1α reduction) are building
Week 2-6
What you might notice
- Gradual improvement in joint stiffness, particularly morning stiffness
- Improved mobility and range of motion as cartilage repair processes mature
- Reduced joint inflammation as TNF-α and IL-1α levels normalize
- Better tolerance for physical activity involving affected joints
What's normal
- Chondrogenic differentiation markers (SOX9, COL2A1, aggrecan) are established and driving matrix production
- SIRT-6 upregulation is supporting cellular longevity in cartilage tissue
- IGF1 stimulation (3.5-5.6 fold) is promoting tissue growth and repair
- Improvements build gradually as new cartilage matrix components are synthesized
What's next
- Benefits continue to develop after the treatment course ends
- Cartilage remodeling is a slow tissue process — improvements may continue for months
- Plan the next course in 3-6 months to reinforce and extend structural benefits
Month 2-6 (inter-course period)
What you might notice
- Sustained improvements in joint function from persistent epigenetic changes
- Ongoing cartilage matrix production from activated chondrogenic programs
- Reduced progression of osteoarthritis symptoms
- Benefits may gradually plateau, indicating readiness for the next treatment course
What's normal
- Epigenetic modifications persist beyond the active treatment period
- Cartilage tissue turnover is slow — structural benefits accumulate over time
- Cyclical treatment every 3-6 months is the standard Khavinson approach
- Each subsequent course builds on tissue improvements from previous treatments
What's next
- Begin the next Cartalax course after 3-6 months
- Consider combining with Sigumir for additional musculoskeletal support
- Maintain physical therapy and joint-friendly exercise alongside bioregulator therapy
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Cartalax over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
How does Cartalax differ from glucosamine and chondroitin?
Glucosamine and chondroitin provide structural building blocks (raw materials) for cartilage repair, while Cartalax works at a fundamentally different level — it activates the genetic programs responsible for building cartilage in the first place. Cartalax upregulates the master chondrogenic transcription factor SOX9 and its downstream targets (type II collagen, aggrecan, COMP), essentially turning on the cell's own cartilage-building machinery. The two approaches are complementary: Cartalax activates the production machinery, while glucosamine/chondroitin provides substrate for that machinery to work with.
What is the senescence-associated secretory phenotype (SASP) and why does it matter?
SASP is a molecular program in which aging, senescent cells stop dividing but remain metabolically active, secreting pro-inflammatory cytokines (TNF-α, IL-1α), matrix-degrading enzymes (MMP-9), and other harmful factors that damage surrounding healthy tissue. In cartilage, SASP drives osteoarthritis progression by creating a toxic microenvironment that accelerates cartilage destruction. Cartalax reverses SASP by normalizing the senescence markers (p16, p21, p53), reducing inflammatory cytokines, and restoring SIRT-6 — the longevity protein whose decline triggers SASP activation.
What clinical evidence supports Cartalax for osteoarthritis?
Cartalax has been used in Russian clinical practice for 15+ years in osteoarthritis patients, with published protocols involving patients ages 52-72 receiving 6 capsules daily for 20-day courses alongside conventional OA treatment. Preclinical evidence is strong: AED peptide at 200 ng/mL activates chondrogenic differentiation in aging stem cells — 10-fold more potent than crude cartilage polypeptide complex — by stimulating SOX9, type II collagen, aggrecan, and COMP. However, large-scale Western randomized controlled trials have not been published.
Why is Cartalax derived from type XI collagen?
The AED amino acid sequence was identified within the alpha-1 chain of type XI collagen — a structural protein essential for cartilage integrity. Type XI collagen helps regulate cartilage fibril diameter and organization. The AED tripeptide functions as a molecular signal that mimics a fragment of this collagen, triggering the cell's own repair and regeneration responses. It does not replace collagen structurally but rather activates the genetic programs for collagen and cartilage matrix production through epigenetic mechanisms.
Can Cartalax rebuild damaged cartilage?
Cartalax activates the cellular programs responsible for cartilage production (SOX9, type II collagen, aggrecan synthesis from stem cells), which represents the most direct peptide-based approach to cartilage regeneration available. However, it is important to set realistic expectations: cartilage is a very slow-turnover tissue, improvements take weeks to months, and severely damaged joints may have limited regenerative capacity. Cartalax is most effective when started early in the osteoarthritis process and combined with physical therapy, weight management, and conventional joint care.
How does Cartalax compare to other Khavinson bioregulators?
Within the Khavinson bioregulator family, Cartalax (AED) is the cartilage/connective tissue specialist. It shares some gene regulatory targets with related peptides — for example, all Glu-Asp-containing peptides modulate MMP-9, Ki-67, and CD98hc — but Cartalax uniquely activates the chondrogenic transcription factor SOX9 and cartilage-specific matrix genes. Sigumir (a joint/bone peptide complex) provides broader musculoskeletal support with multiple peptide components, while Cartalax offers the targeted action of a single defined tripeptide with established molecular mechanisms.
Further reading
History & related research
History · since 1999
Cartilage's molecular messenger: Khavinson's synthetic bioregulator for musculoskeletal regeneration
CARTALAX is a synthetic tripeptide bioregulator (Ala-Glu-Asp, AED) developed by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology.
Read the full history of CartalaxReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Cartalax, on one page.